Cardiovascular Disease: Much More Aggressive in Patients with Type 2 Diabetes

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2002 Feb 2

PMID 11822977

Citations 6

Authors

Elaine Chiquette

Robert Chilton

Affiliations

Soon will be listed here.

Abstract

It is estimated that 80% of individuals with type 2 diabetes die of coronary heart disease. Several factors have been found to contribute to the accelerated atherosclerosis present in diabetic patients. These include hyperglycemia-induced endothelial cell dysfunction, impaired fibrinolysis, increased platelet aggregation, and dysfunctional arterial remodeling. The evidence supports that a healthy lifestyle, statin drugs, angiotensin-converting enzyme inhibitors, and aspirin can modify these factors and slow the atherosclerosis process observed in type 2 diabetes. Because of the high prevalence of cardiovascular disease in people with type 2 diabetes, early cardiac testing is indicated. The optimal strategy for coronary revascularization in diabetic patients remains controversial and is discussed in detail in this review.

Citing Articles

Bridging the Gap Between Diabetes and Stroke in Search of High Clinical Relevance Therapeutic Targets.

Coppola T, Beraud-Dufour S, Lebrun P, Blondeau N Neuromolecular Med. 2019; 21(4):432-444.

PMID: 31489567 DOI: 10.1007/s12017-019-08563-5.

Natural Phyto-Bioactive Compounds for the Treatment of Type 2 Diabetes: Inflammation as a Target.

Gothai S, Ganesan P, Park S, Fakurazi S, Choi D, Arulselvan P Nutrients. 2016; 8(8).

PMID: 27527213 PMC: 4997374. DOI: 10.3390/nu8080461.

A prospective study of fasting plasma glucose and risk of stroke in asymptomatic men.

Sui X, Lavie C, Hooker S, Lee D, Colabianchi N, Lee C Mayo Clin Proc. 2011; 86(11):1042-9.

PMID: 21911559 PMC: 3202993. DOI: 10.4065/mcp.2011.0267.

P2X(7) Receptors in Neurological and Cardiovascular Disorders.

Skaper S, Debetto P, Giusti P Cardiovasc Psychiatry Neurol. 2009; 2009:861324.

PMID: 20029634 PMC: 2794459. DOI: 10.1155/2009/861324.

Enhanced spontaneous thrombolysis: a new therapeutic challenge.

Kovacs I, Gorog D, Yamamoto J J Thromb Thrombolysis. 2006; 21(3):221-7.

PMID: 16683213 DOI: 10.1007/s11239-006-6579-0.

References

. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355(9200):253-9. View

Perry I, Wannamethee S, Walker M, Thomson A, Whincup P, Shaper A . Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. BMJ. 1995; 310(6979):560-4. PMC: 2548938. DOI: 10.1136/bmj.310.6979.560. View

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):145-53. DOI: 10.1056/NEJM200001203420301. View

Chan J, Rimm E, Colditz G, Stampfer M, Willett W . Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994; 17(9):961-9. DOI: 10.2337/diacare.17.9.961. View

Jarrett R, Shipley M . Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease--putative association via common antecedents; further evidence from the Whitehall Study. Diabetologia. 1988; 31(10):737-40. DOI: 10.1007/BF00274775. View

Fuller J, Keen H, Jarrett R, Omer T, Meade T, Chakrabarti R . Haemostatic variables associated with diabetes and its complications. Br Med J. 1979; 2(6196):964-6. PMC: 1596588. DOI: 10.1136/bmj.2.6196.964. View

Kornowski R, Mintz G, Lansky A, Hong M, Kent K, Pichard A . Paradoxic decreases in atherosclerotic plaque mass in insulin-treated diabetic patients. Am J Cardiol. 1998; 81(11):1298-304. DOI: 10.1016/s0002-9149(98)00157-x. View

Rimm E, Chan J, Stampfer M, Colditz G, Willett W . Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. BMJ. 1995; 310(6979):555-9. PMC: 2548937. DOI: 10.1136/bmj.310.6979.555. View

Hu F, Stampfer M, Solomon C, Liu S, Colditz G, Speizer F . Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med. 2001; 134(2):96-105. DOI: 10.7326/0003-4819-134-2-200101160-00009. View

10.

Kannel W, DAgostino R, Wilson P, Belanger A, Gagnon D . Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990; 120(3):672-6. DOI: 10.1016/0002-8703(90)90026-t. View

11.

Chiariello M, Indolfi C, Cotecchia M, Sifola C, Romano M, Condorelli M . Asymptomatic transient ST changes during ambulatory ECG monitoring in diabetic patients. Am Heart J. 1985; 110(3):529-34. DOI: 10.1016/0002-8703(85)90070-5. View

12.

Haffner S, Lehto S, Ronnemaa T, Pyorala K, Laakso M . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339(4):229-34. DOI: 10.1056/NEJM199807233390404. View

13.

Tomita H, Egashira K, Usui M, Koyanagi M, Shimokawa H, Takeya M . Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol. 1998; 18(9):1456-64. DOI: 10.1161/01.atv.18.9.1456. View

14.

. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1997; 96(6):1761-9. DOI: 10.1161/01.cir.96.6.1761. View

15.

Niles N, McGrath P, Malenka D, Quinton H, Wennberg D, SHUBROOKS S . Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol. 2001; 37(4):1008-15. DOI: 10.1016/s0735-1097(00)01205-5. View

16.

. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994; 308(6921):81-106. PMC: 2539220. View

17.

Rimm E, Manson J, Stampfer M, Colditz G, Willett W, Rosner B . Cigarette smoking and the risk of diabetes in women. Am J Public Health. 1993; 83(2):211-4. PMC: 1694562. DOI: 10.2105/ajph.83.2.211. View

18.

Kawakami N, TAKATSUKA N, Shimizu H, Ishibashi H . Effects of smoking on the incidence of non-insulin-dependent diabetes mellitus. Replication and extension in a Japanese cohort of male employees. Am J Epidemiol. 1997; 145(2):103-9. DOI: 10.1093/oxfordjournals.aje.a009080. View

19.

. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339(19):1349-57. DOI: 10.1056/NEJM199811053391902. View

20.

Turner R, Millns H, Neil H, Stratton I, Manley S, Matthews D . Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998; 316(7134):823-8. PMC: 28484. DOI: 10.1136/bmj.316.7134.823. View